The Experience Matters. Let us show you why.
Contact us today.
Clinical Trials & REMS in the Time of Corona: FDA & MHRA Advice and Guidance
Bart Cobert / Apr 09, 2020
Pharmacovigilance expert Bart Cobert discusses the FDA and MHRA guidance for non-Corona related clinical trials.
Read More
Does Rapid FDA Approval Produce Drug Safety Issues?
Bart Cobert / Mar 16, 2020
Bart Cobert gives his pharmacovigilance point of view on a recent paper on FDA approval timelines and drug safety issues.
Read More
Clintrials.gov Update
Bart Cobert / Feb 11, 2020
Bart Cobert on the importance of publishing clinical trials data and implications on pharmacovigilance.
Read More
Pharmacovigilance 2030
Bart Cobert / Dec 11, 2019
This is an interesting article looking at what PV will be in the year 2030.
Read More
FDA Draft Guidance on PMRs
Bart Cobert / Nov 24, 2019
Bart Cobert highlights the most important changes in the recently revised FDA draft guidance on PMRs.
Read More
Ranitidine – What Happened and What Do We Learn?
Bart Cobert / Oct 31, 2019
Bart Cobert explores several important points to take from the still ongoing signal and safety issue with Renitidine recall.
Read More
Vaping – A Serious Safety Signal
Bart Cobert / Oct 07, 2019
Bart Cobert discusses the major safety issue in the US on e-cigarettes and vaping.
Read More
Importing Canadian Drugs to the US
Bart Cobert / Aug 29, 2019
Bart Cobert covers several issues involved in setting up the proposed "Safe Importation Plan" which aims to allow US consumers to get safe and cheaper drugs.
Read More
No-No’s in Drug Safety
Bart Cobert / Aug 13, 2019
An overview covering a number of things to avoid doing when it comes to drug safety.
Read More
Different Regulatory Actions from Different Agencies
Bart Cobert / Jun 27, 2019
Bart Cobert explores the potential reasons for the differing regulatory actions from the different agencies.
Read More
